We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. AstraZeneca PLC is placed fourth on our list among the ...

AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter.

AstraZeneca PLC ADR stock grades by Barron's. View AZN fundamental and sentiment analysis powered by MarketGrader.

AstraZeneca PLC (NASDAQ:AZN) is one of the best performing pharma stocks in 2025. On January 7, Berenberg Bank reiterated a ...

This marks Enhertu's sixth approved indication in the country, Daiichi noted. Back in 2020, the China Center for Drug Evaluation designated Enhertu a "breakthrough therapy" for the second-line gastric ...

The Nasdaq-100 Index is a globally recognized index that tracks the performance of 100 of the largest non-financial companies ...

The pharmaceutical sector mainstay reported good news about its developmental hypertension drug. It purchased the medicine's maker, CinCor Pharma, in early 2023. Early this morning, AstraZeneca shared ...

EsoBiotec SA, a biotechnology company specializing in in vivo cell therapies, has announced a definitive agreement to be acquired by AstraZeneca PLC (NYSE:AZN). The agreement represents a major step ...

January 2026 AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock ExchangeTicker symbol for ordinary shares will remain AZN AstraZeneca PLC ("Astr ...

(Alliance News) - Daiichi Sanyko Co Ltd on Monday said EU regulators had validated an application for its breast cancer treatment, Enhertu with pertuzumab, jointly developed with AstraZeneca PLC. This ...